+44 115 974 9000
Quotient Sciences is dedicated to accelerating the development of new drugs for patients around the world
We provide formulation development, clinical pharmacology trials, and clinical and commercial manufacturing services to the pharmaceutical and biotech industry. These services are provided either individually or as an integrated service offering via our Translational Pharmaceutics® platform.
Translational Pharmaceutics® accelerates drug development by integrating formulation development, real-time manufacturing and clinical testing. The platform is unique to Quotient Sciences and has been used over the last decade by global pharmaceutical and biotech companies across over 400 drug programs.
Quotient Sciences has almost 30 years of experience developing a breadth of pharmaceutical formulations across a range of indications. Our innovative approach to formulation development integrates drug product development with clinical evaluation, combined with our experience with over 1,500 molecules at all stages of drug development.
Understanding that early phase clinical testing is a pivotal milestone in the development of your drug product, Quotient offers a clinical trial manufacturing, testing and certification service designed to meet your individual requirements. Our innovative method of building integrated GMP and GCP programs provides you with a streamlined, flexible approach to drug product supply that reflects your clinical study design and timeline. We understand the time and cost pressures you face during early phase evaluation and work with you to ensure a rapid, seamless path from development to clinical trial supply.
When you are looking for a partner who is dedicated to Phase I trials and early clinical development, rely on Quotient Sciences for the experience and expertise to seamlessly deliver your studies with the highest quality service and speed. We accelerate your molecule from first-in-human to proof-of-concept, helping you make critical decisions earlier and faster. Whatever Phase I clinical pharmacology study you require, you can expect a fully integrated program from study design and start-up to data reporting.
Quotient Sciences is a global player in commercial drug product manufacture of small molecule products for niche therapies including oncology and orphan drugs. Our commercial manufacturing facility located in Philadelphia is designed to handle your high-potency compounds.
Download the white paper 'Assessing the Financial Impact of Translational Pharmaceutics'
You need data rapidly to make crucial decisions during a study. Faster data means we can provide our customers with earlier interim data and interim PK reports for on-study dosing and formulation decisions. We understand on-study changes to early phase study designs and dosing are frequent and so our study strategy for study database design and reporting is built around flexibility and rapid implementation. We use eSource data collection procedures in our clinical units and a joint eSource/eCRF database. Data are available in the study database within hours of collection, ready for remote sponsor access.
Our Drug Development Consultants work with you to design and implement successful drug development programs. With industry leading scientific expertise across a range of technical disciplines, we help customers across all stages of development, from candidate selection to commercial launch. Our consultants have a proven track-record of cutting across industry silos to reduce the time and cost of development. With hands-on development experience across hundreds of drug molecules and product types, we’ll help you avoid critical pitfalls, manage risks and maximise the potential for success.
Join Nazim Kanji and Peter Scholes at the 13th Annual EuPFI Conference this year to discuss your pediatric program challenges and needs.— Quotient Sciences (@Quotient_Sci) September 20, 2021
Find out more and get in touch now to schedule a meeting
> https://t.co/cTWhu3C7bu <#Pediatric #CRO #CDMO #TasteMasking #Pharma #Biotech pic.twitter.com/r4ADEYDr9l
Latest scientific poster.— Quotient Sciences (@Quotient_Sci) September 17, 2021
This poster details an integrated radiolabelled study for Nolasiban, an orally active oxytocin receptor antagonist, in healthy female subjects.
Download here >> https://t.co/9uQ2HWqzTG <<#Metabolite #Bioavailability #ADME #CDMO #Pharma pic.twitter.com/wj8O9sTGUP